Idexx Beats Q3 Estimates, Raises Outlook

The veterinary diagnostics maker reported third-quarter results above analyst forecasts for both earnings and revenue.

Updated on Nov. 2, 2026 in Economic Indicators

Isometric editorial illustration of a smooth unlabeled benchtop diagnostic analyzer beside a stepped row of sample cartridges on a matte lab surface, in deep teal, cream, and mustard. — Idexx Laboratories reported third-quarter net income of $317.1 million, or $4.01 per share, and raised its full-year outlook after beating analyst estimates. AI Illustration. Upload story photo >

Idexx Laboratories reported third-quarter net income of $317.1 million, or $4.01 per share, and revenue of $1.21 billion. Adjusted earnings of $3.98 per share topped the analyst average estimate of $3.71 per share.

Why it matters

The results point to continued demand for the company's veterinary testing products, with revenue exceeding the analyst estimate of $1.19 billion. Full-year guidance for both earnings and revenue offers a view of the company's expected trajectory for the rest of the year.

Idexx reported third-quarter net income of $317.1 million, or $4.01 per share, and adjusted earnings of $3.98 per share versus an analyst average of $3.71. Full-year guidance calls for earnings of $14.96 to $15.16 per share and revenue of $4.74 billion to $4.77 billion.

The players

Idexx Laboratories

Idexx Laboratories is a Westbrook, Maine-based company that develops diagnostic tests and software for veterinary and water testing.

The details

Idexx, headquartered in Westbrook, Maine, reported third-quarter revenue of $1.21 billion, which surpassed the analyst estimate of $1.19 billion. The company also issued full-year projections for both earnings and revenue.

November 2, 2026: Idexx reported third-quarter earnings.

Market Landscape

The quarter beat analyst consensus on both earnings and revenue, and the company set full-year guidance of $14.96 to $15.16 per share. Results measured against consensus estimates are the standard yardstick investors use to judge quarterly performance in this sector.

Pet owners and veterinary clinics that rely on Idexx testing products may see the company's continued demand reflected in its product availability and pricing over time. Investors holding shares in the company can track the full-year guidance as the year progresses.

The takeaway

Quarterly beats paired with raised guidance signal management's confidence in demand for the rest of the year. Readers following the company can compare future results against the stated full-year ranges to gauge whether that confidence holds.